The Best Advice is Free – From Conflicts of Interest

Statement of CSPI Integrity in Science Director Merrill Goozner on S.3807

November 15, 2006

There are three crucial FDA advisory committee meetings coming up in December. One will discuss drug-eluting stents on December 7-8; one will discuss antidepressant use and adult suicidality on December 13; and one will discuss the antibiotic Ketek on December 14-15.

Nothing in S. 3807, the FDA reform bill sponsored by Sen. Mike Enzi (R-WY) and Sen. Edward Kennedy (D-MA), would require the scientists who will sit on those panels to be free from financial ties to the manufacturers of those products. This is unacceptable.

The scientists who advise the FDA should be free of all financial ties to firms whose products are under review. The public’s faith in the integrity of the process will be undermined by any reform legislation that allows physicians and scientists with conflicts of interest to continue serving on these committees.

For a copy of CSPI's written testimony submitted to the Health, Education, Labor and Pensions Committee on S.3807, click here.



Get Updates Via Email

Journalists can receive CSPI news releases via email.
Not a journalist?

Sign Up for Email Now



Subscribe Now

Subscribe Now »

Subscribe Today and Save!

In Recent Issues

Cover Story: 1 in 8: What You May Not Know About Breast Cancer

Special Feature: Soy Oh Soy: Is It Really Bad For You?

Brand-Name Rating: Pasta Sauce

Subscribe Now

Request permission to reuse content

The use of information from this site for commercial purposes is strictly prohibited without written permission from CSPI.